SCHEMBL975521

SCHEMBL975521

c1ccc(COc2ccc(C3(c4ccc(-c5cccnc5)cc4)CCC3)cc2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.45
▸ CYP2D6 P10635 3/20 0.45
▸ CYP2C9 P11712 3/20 0.45
▸ CYP19A1 P11511 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ALOX5AP P20292 3/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ HSD11B1 P28845 4/20 0.41
▸ NR1I2 O75469 2/20 0.41
▸ PARP10 Q53GL7 1/20 0.41
▸ IDO1 P14902 1/20 0.40
▸ GRM5 P41594 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ PDE10A Q9Y233 2/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL977196 0.97 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9CYP19A1CYP2C19
SCHEMBL976155 0.88 MAPK14 (0.47) CYP3A4CYP2D6CYP2C9KDM4EALDH1A1
SCHEMBL977680 0.85 MAPK14 (0.47) CYP3A4CYP2D6CYP2C9KDM4EALDH1A1
SCHEMBL975773 0.83 CYP1A2 (0.47) CYP3A4CYP2D6CYP2C9CYP19A1CYP2C19
SCHEMBL977752 0.82 PARP10 (0.50) CYP3A4CYP2D6CYP2C9CYP2C19KDM4E
SCHEMBL974877 0.77 NPC1 (0.44) KDM4EALDH1A1SMN1; SMN2ALOX5APHSD11B1
SCHEMBL975580 0.77 PARP10 (0.57) KDM4EALDH1A1SMN1; SMN2ALOX5APPARP10
SCHEMBL978365 0.76 MAPT (0.43) CYP3A4CYP2C9KDM4EALDH1A1SMN1; SMN2
SCHEMBL19238851 0.76 CYP2A6 (0.56) CYP3A4ALDH1A1SMN1; SMN2ALOX5APCYP1A2
SCHEMBL19238853 0.76 CYP2A6 (0.52) CYP3A4ALDH1A1ALOX5APCYP1A2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003815-A1 DIPHENYL SUBSTITUTED CYCLOALKANES MERCK & CO., INC. 2011-01-06 — — US disclosed
EP-2209761-A1 DIPHENYL SUBSTITUTED CYCLOALKANES Merck Sharp & Dohme Corp. (US) 2010-07-28 — — EP disclosed
WO-2009048547-A1 DIPHENYL SUBSTITUTED CYCLOALKANES MERCK & CO., INC. (US) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003815-A1 DIPHENYL SUBSTITUTED CYCLOALKANES PTGIS, PTGS1, LTC4S CYP3A4 924/4885CYP2D6 615/4885CYP2C9 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback